Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today the treatment and successful operation of the first patient in a Phase I clinical trial. The study, sponsored by VAXIMM, will initially enroll six patients with operable recurrence of a glioblastoma (brain tumor) and is being conducted at the University Hospital in Heidelberg, Germany.